Sunday, July 12, 2020

Renovion Raises $8.1M to Support CF Lung Inflammation, Mucus Therapy

Transplant News Sharing // News from Source

Renovion has raised $8.1 million in a financing round, supporting further development and planned clinical testing of ARINA-1, a nebulized treatment for chronic lung diseases like cystic fibrosis (CF) and non-CF bronchiectasis, and for lung transplants.

“Patient and laboratory studies have shown that ARINA-1 significantly improves mucus clearance while reducing inflammation. There are limited options available and we see a great opportunity to help these patients,” Dan Copeland, CEO at Renovion, said in a press release. “This funding will be instrumental in progressing our clinical [lung disease] programs.” 

ARINA-1 works to restore the lungs’ innate immune system, the first line of defense against microbes and foreign particles, to improve mucus clearance and lower inflammation. The innate immune system is activated when it comes into contact with foreign bodies.

“My lab has worked extensively with ARINA-1 to determine how the drug effects CF mucus and mucus transport. CF mucus is severely problematic, and ARINA-1 strongly augments mucus transport in CF cells that are defective for this trait,”said Steven Rowe, MD, director of the Cystic Fibrosis Research Center at the University of Alabama Birmingham.

The candidate treatment is inhaled using an investigational eFlow nebulizer by Pari Group, being developed to deliver an optimal therapy dose to the airways. Patient data shows a good safety profile and significant mucus clearance with ARINA-1 therapy, Renovion reported on its website.A Phase 2/3 pivotal clinical trial assessing ARINA-1 in people who have had a lung transplant is planned for early 2021, followed by clinical trials in CF and non-CF bronchiectasis patients.“Based on our studies demonstrating that ARINA-1 is substantially more effective than hypertonic saline for mucus clearanc [mucus thinners] in CF cells, the potential for ARINA-1 to help people with CF improve clinically is promising,” Rowe said.

“Importantly, CF mucus is emblematic of difficult to treat mucus in other airway diseases. As ARINA-1’s mechanism is multi-faceted, it also has the potential to help in other diseases,” he added.

ARINA-1 has been designated an orphan drug as a potential treatment of lung transplant complications and CF by the U.S. Food and Drug Administration. 

The Series A financing round was led by White Rock Capital Management.

Patricia Silva, PhD
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Transplant News Sharing // “Lung Transplants” – Google News from Source

Transplant News
Transplant News
Transplant News brings you original and carefully curated aggregate news stories, articles and content that matter to the transplant community, from top publishers around the web. Everything from patient stories, to the latest in transplant innovation, TN is your window into the world of transplantation.

Facebook Comments


Must Read

Is tandem transplant appropriate for patients with high-risk neuroblastoma?

Transplant News Sharing // News from Source ...

A Stem Cell Transplant Has Cured Two HIV Patients – Now. Powered by Northrop Grumman

Transplant News Sharing // News from Source Human immunodeficiency virus (HIV) has been traced as far back as a century ago, but it wasn’t...

Young mother in “desperate” need of kidney transplant

Transplant News Sharing // News from Source WAUSAU, Wis. (WSAW) - There are nearly 114,000 people on the national waiting list for organ transplants...

Wakefield bride-to-be born suffering from cancer needs second life-saving liver transplant before marrying fiance

Transplant News Sharing // News from Source Rebecca Gough and James Towse.Rebecca Gough - who said she needs a full transplant within 12-months...

Not just COVID-19, shortness of breath could be a symptom of heart failure

Transplant News Sharing // News from Source ...